ABEO
Abeona Therapeutics Inc.
Set alert
4.35 USD -0.21 -4.61%
4.31 Day range 4.53
4.17 52-week range 7.46
- YTD
- -17.46%
- 1 year
- -14.37%
- Open
- 4.50
- Prev close
- 4.56
- Mkt cap
- 248.75M
- Vol
- 783.43K
- Avg vol
- 1.35M
- EPS
- -1.18
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 4.31
- High
- 4.53
- Forward P/E
- -3.84
- Beta
- 1.50
- Short ratio
- 10.79
- Inst. own
- 77.54%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 6.15
- 200-d avg
- 5.64
- 1y target
- 16.75
Key statistics
- Market cap
- 246.92M
- Enterprise value
- 158.18M
- Trailing P/E
- 0.00
- Forward P/E
- -3.84
- PEG ratio
- 0.00
- Price / book
- 10.16
- EPS (TTM)
- -2.05
- Beta
- 1.50
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -20.50M
- Total cash
- 122.71M
- Total debt
- 23.16M
- Return on equity
- -127.38%
- Shares outstanding
- 43.47M
- Short % of float
- 6.29%
- 50-day average
- 6.15
- 200-day average
- 5.64
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 16.75 +285.1% upside
Now 4.35
- Target (low)
- 9.50
- Target (mean)
- 16.75
- Target (high)
- 21.00
Ratings (0m) 5 5 buy · 0 hold · 0 sell
- Strong buy1
- Buy4
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.34.
Financials — quick view
ABEO Revenue — quarterly 11.38M
ABEO Net income — quarterly -20.19M
ABEO EPS — quarterly -0.35
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | -0.38 | -0.31 | +0.07 | +18.42% |
| Aug 12, 2024 | Jun 1, 2024 | -0.33 | -0.75 | -0.42 | -127.27% |
| May 15, 2024 | Mar 1, 2024 | -0.47 | -0.53 | -0.06 | -12.77% |
| Mar 18, 2024 | Dec 1, 2023 | -0.51 | -0.64 | -0.13 | -25.49% |
| Nov 13, 2023 | Sep 1, 2023 | -0.53 | -0.48 | +0.05 | +9.43% |
| Aug 8, 2023 | Jun 1, 2023 | -0.66 | -0.44 | +0.22 | +33.33% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 25, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 31, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 29, 2024 | Cantor Fitzgerald | reit | Overweight | Overweight |
| Aug 14, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jul 12, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jul 3, 2024 | HC Wainwright & Co. | init | — | Buy |
About Abeona Therapeutics Inc.
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in Cleveland, Ohio.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- abeonatherapeutics.com
News
- Abeona Therapeutics Inc. (NASDAQ:ABEO) Stock Has Consensus Target Price of $21.00
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO
- Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO
- Abeona Therapeutics Highlights ZEVASKYN Launch Momentum, Revenue Growth at H.C. Wainwright
- Abeona Expands ZEVASKYN Network as RDEB Launch Gains Momentum
- Apple To Rally Around 13%? Here Are 10 Top Analyst Forecasts For Friday
Your note
Sign in to keep a note on ABEO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALLAND LEILA | Director | Stock Award(Grant) | Aug 25, 2024 | 118,265 |
| ALVINO MARK J. | Director | Stock Award(Grant) | Aug 25, 2024 | 72,334 |
| AMOROSO MICHAEL | Director | Stock Award(Grant) | Aug 25, 2024 | 144,365 |
| CHARLES FAITH L. | Director | Stock Award(Grant) | Aug 25, 2024 | 113,731 |
| CROMBEZ ERIC M.D. | Director | Stock Award(Grant) | Aug 12, 2024 | 11,044 |
| O'MALLEY BRENDAN M | General Counsel | Stock Award(Grant) | Jul 7, 2024 | 280,364 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Suvretta Capital Management, LLC | 8.48% | 3,685,503 | 20.93M | Sep 29, 2024 |
| Nantahala Capital Management, LLC | 7.90% | 3,432,637 | 19.50M | Sep 29, 2024 |
| Adage Capital Partners GP L.L.C. | 7.48% | 3,249,994 | 18.46M | Sep 29, 2024 |
| Millennium Management Llc | 5.29% | 2,301,628 | 13.07M | Sep 29, 2024 |
| Vanguard Group Inc | 4.62% | 2,007,626 | 11.40M | Sep 29, 2024 |
| Vivo Capital, LLC | 4.24% | 1,842,751 | 10.47M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.84% | 1,232,465 | 7.00M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.62% | 703,062 | 3.99M | Sep 29, 2024 |
| Simplify Exchange Traded Fds-Simplify Propel Opportunities ETF | 0.94% | 408,584 | 2.32M | Sep 29, 2024 |
| abrdn Life Sciences Investors | 0.75% | 326,995 | 1.86M | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.53% | 229,139 | 1.30M | Oct 30, 2024 |
| iShares Micro Cap ETF | 0.21% | 89,297 | 507.21K | Oct 30, 2024 |